BRPI0510719A - derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos - Google Patents

derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos

Info

Publication number
BRPI0510719A
BRPI0510719A BRPI0510719-9A BRPI0510719A BRPI0510719A BR PI0510719 A BRPI0510719 A BR PI0510719A BR PI0510719 A BRPI0510719 A BR PI0510719A BR PI0510719 A BRPI0510719 A BR PI0510719A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
derivatives
naphthalimide derivatives
naphthalimide
Prior art date
Application number
BRPI0510719-9A
Other languages
English (en)
Inventor
Eric Van Quaquebeke
Gentiane Simon
Laurent Van Den Hove
Robert Kiss
Francis Darro
Original Assignee
Unibioscreen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unibioscreen Sa filed Critical Unibioscreen Sa
Publication of BRPI0510719A publication Critical patent/BRPI0510719A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/14Aza-phenalenes, e.g. 1,8-naphthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE NAFTALIMIDA, COMPOSIçãO FARMACêUTICA, USO E MéTODO DE PREPARAçãO DOS MESMOS. A presente invenção refere-se a derivados de naftalimida substituída, sais farmaceuticamente aceitáveis dos mesmos e solvatos dos mesmos, que são utilizáveis para fabricar composições farmacêuticas para o tratamento de doenças proliferativas de células como câncer. A invenção também provê métodos para fabricar estes derivados.
BRPI0510719-9A 2004-05-05 2005-05-04 derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos BRPI0510719A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56846904P 2004-05-05 2004-05-05
EP04447114 2004-05-05
PCT/BE2005/000069 WO2005105753A2 (en) 2004-05-05 2005-05-04 Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom

Publications (1)

Publication Number Publication Date
BRPI0510719A true BRPI0510719A (pt) 2007-11-20

Family

ID=34970401

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510719-9A BRPI0510719A (pt) 2004-05-05 2005-05-04 derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos

Country Status (8)

Country Link
US (1) US20070117836A1 (pt)
EP (1) EP1742920A2 (pt)
JP (1) JP2007536283A (pt)
AU (1) AU2005238096A1 (pt)
BR (1) BRPI0510719A (pt)
CA (1) CA2555718A1 (pt)
MX (1) MXPA06012660A (pt)
WO (1) WO2005105753A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AU2007247355A1 (en) * 2006-05-05 2007-11-15 Unibioscreen S.A. 5-urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
JP6120311B2 (ja) * 2013-02-12 2017-04-26 学校法人銀杏学園 ポリフェノール化合物
CN103113300A (zh) * 2013-03-06 2013-05-22 广西中医药大学 一种具有抗肿瘤活性的化合物的制备方法和用途
JP6605513B2 (ja) 2014-07-01 2019-11-13 第一三共株式会社 抗菌剤としての三環式ベンゾオキサボロール
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
CN112940059B (zh) * 2021-02-06 2022-05-27 河南大学 一种糖基修饰的萘酰亚胺-多胺缀合物、其制备方法及应用
CN116410233B (zh) * 2023-02-27 2024-08-09 河南大学 一种靶向TNBC的Pt(IV)-萘酰亚胺多胺配合物、其制备方法及应用
CN119119131B (zh) * 2024-09-11 2026-03-20 河南大学 一种基于Lamp2介导的能够逆转胶质瘤进展的萘酰亚胺-铂(IV)配合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES459497A1 (es) * 1977-06-04 1978-04-16 Made Labor Sa Un metodo para la preparacion industrial de naftalimidas y sus derivados.
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
DE3614414A1 (de) * 1986-04-29 1987-11-05 Knoll Ag Neue benzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE4232739A1 (de) * 1992-09-30 1994-03-31 Knoll Ag Neue asymmetrisch substituierte bis-Naphthalimide
IL110460A (en) * 1993-08-18 2001-01-11 Basf Ag Bis-naphthalimides, their preparation and pharmaceutical compositions containing them
US6552544B2 (en) * 2001-04-05 2003-04-22 Varian, Inc. Detunable coil assembly and method of detuning RF coil for MRI
US6693198B2 (en) * 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
AU2005209845A1 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by N-acetyl transferase genotyping

Also Published As

Publication number Publication date
JP2007536283A (ja) 2007-12-13
EP1742920A2 (en) 2007-01-17
US20070117836A1 (en) 2007-05-24
WO2005105753A3 (en) 2006-02-02
WO2005105753A8 (en) 2006-10-12
CA2555718A1 (en) 2005-11-10
MXPA06012660A (es) 2007-03-23
AU2005238096A1 (en) 2005-11-10
WO2005105753A2 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
CR11199A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112012008849A2 (pt) composto, composição farmacêutica, e, uso de um composto
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
UY32203A (es) Amino pirimidinas y su uso en terapia
BRPI0915084B8 (pt) composto, e, composição farmacêutica
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
BR122013028005B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CR11857A (es) Compuestos pirazolicos 436
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
UY28271A1 (es) Compuestos químicos
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.